Collaboration – November 3, 2026
The Novo Nordisk Foundation and the European Vaccine Initiative (EVI) have launched AVANT-guard, a three-year network that aims to make mucosal immunity a recognized basis for the regulatory approval of airway vaccines.
In a new job – November 3, 2026
Anders Andersson has been appointed CEO of Mölnlycke Health Care and Fredrik Wallefors President Surgical, both effective January 1, 2027.
Pharma Business – November 3, 2026
Danish Bavarian Nordic has been awarded a new four-year contract by the UK Government to supply its mpox and smallpox vaccine MVA-BN.
Intellectual Property – November 3, 2026
The US Patent and Trademark Office has granted Moberg Pharma a patent covering an improved dosing regimen for MOB-015, the company’s topical treatment for nail fungus. The US is the first market to approve a patent application on the improved dosing.
Clinical Trials – November 3, 2026
Lytix Biopharma’s Phase II NeoLIPA study, which gives ruxotemitide with pembrolizumab before surgery in patients with resectable melanoma, has met its primary endpoint of pathological complete response (pCR).
Biotech Business – November 3, 2026
Rayca Precision, which operates in Helsinki and London, has partnered with Dutch TechBio company QurieGen to offer pharma and biotech R&D teams a joint workflow that connects the discovery of new drug targets with the design and testing of drug candidates.
Clinical Trials – November 3, 2026
Lytix Biopharma’s Phase II NeoLIPA study, which gives ruxotemitide with pembrolizumab before surgery in patients with resectable melanoma, has met its primary endpoint of pathological complete response (pCR).
Clinical Trials – October 29, 2026
Sobi’s pozdeutinurad significantly lowered serum uric acid levels in patients with uncontrolled gout, with the effect sustained for a full year, according to new Phase III data from the pivotal REDUCE-2 study. The results will be presented in a late-breaking session at ACR Convergence 2026.
Clinical Trials – October 28, 2026
Copenhagen-based Genmab says its bispecific antibody petosemtamab, given with pembrolizumab, met both primary endpoints in the global Phase III LiGeR-HN1 trial in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma.
Clinical Trials – October 28, 2026
Swedish biotech Vicore Pharma’s Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) has passed a pre-planned futility analysis. The independent Data Monitoring Committee recommended that the trial continue without modification, and topline results remain on track for mid-2027.
Clinical Trials – October 27, 2026
The final clinical study report from DexTech Medical’s study of OsteoDex in treatment-resistant multiple myeloma confirms the earlier preliminary results. No serious adverse events were reported, and the disease stabilized in all patients during treatment.
Clinical Trials – October 26, 2026
Finnish TILT Biotherapeutics has presented Phase Ib results at ESMO 2026 showing that four of nine evaluable patients with platinum-resistant ovarian cancer responded to its candidate TILT-123 combined with immunotherapy and chemotherapy. Two of the patients achieved complete responses.
PharmaRelations
Do you have a strong network in the Finnish Life Science industry and enjoy turning relationships into business opportunities?
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
In a new job – November 1, 2026
Swedish Cantargia has appointed Monic Stuart, MD, as Chief Medical Officer, and Norwegian radiopharmaceutical company Oncoinvent has named Zuzana Jiráková Trnková, MD, PhD, to the same role.
In a new job – October 28, 2026
Vitrolife Group has appointed Elin Frostehav as President and CEO. She will take up the role as soon as practicable and no later than May 1, 2027. Until then, Rickard Ericsson, Senior Vice President Innovation, is interim CEO from November 1, succeeding Bronwyn Brophy O’Connor.
In a new job – October 27, 2026
Swedish peptide purification company Nanologica has appointed board member Mark Quick as CEO as it shifts its commercial focus toward North America and Europe. The company also plans a rights issue of approximately SEK 110.5 million.
Careers article – October 20, 2026
Stamina, mentors, passion, and a life outside the lab. When Nordic Life Science profiled five leaders from across the region’s life science industry, from investors to a startup founder to two of its leading scientists, each shared advice for people starting out. Their answers had a lot in common.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Pharma Business – November 3, 2026
AstraZeneca has started a three-year program, Reshaping for Sustainable Growth, that is expected to deliver USD 1.5 billion in annual pre-tax savings to be reinvested mainly in its pipeline. The company announced it alongside third-quarter results showing total revenue up 7% at constant exchange rates.
Pharma article – November 2, 2026
Bavarian Nordic will donate 75,000 doses of its MVA-BN mpox vaccine to a newly established global mpox vaccine emergency stockpile, and has also been awarded a contract to supply a further 150,000 doses.
Pharma Business – October 29, 2026
The US Food and Drug Administration (FDA) has accepted Uppsala-based Orexo’s resubmitted New Drug Application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose. A decision is expected by March 29, 2027.
Acquisition – November 1, 2026
Swedish SenzaGen has agreed to acquire Alcyomics, a UK company that tests drug candidates for immune-related side effects without using animals. The initial price is approximately SEK 28 million, and the deal takes SenzaGen into safety testing of biological drugs such as antibodies and T-cell engagers.
Business Award – October 30, 2026
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award.
MedTech Business – October 29, 2026
Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).
Biotech Business – November 2, 2026
Swedish biotech BioInvent plans a rights issue of approximately SEK 430 million to fund development of its anti-TNFR2 antibody BI-1808 and its other priority programs. The company also proposes to cut up to 20 positions.
Acquisition – November 2, 2026
Lund-based Alligator Bioscience has agreed to sell all rights and assets related to its CD40 agonist antibody mitazalimab to Biossil. The deal includes an upfront payment of USD 0.75 million, milestone payments of up to USD 108 million, and royalties on future sales.
Biotech Business – October 27, 2026
The US Food and Drug Administration has approved Xbrane Biopharma’s Lucamzi (ranibizumab-blrz) as a biosimilar to Lucentis. The approval gives US patients a lower-cost option for treating wet age-related macular degeneration (AMD) and other serious eye conditions.
Funding – October 30, 2026
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily.
Funding – October 27, 2026
Researchers at Karolinska Institutet have been granted a total of SEK 59 million from the Swedish research council Formas for two new research programs on how climate change affects human health.
Science Award – October 27, 2026
Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.
This site uses cookies
